BRPI0809837A2 - "COMPOSITION FOR TREATING MENTAL DISORDERS, BALANCE OF COMPOSITE FOR TREATING MENTAL DISORDERS, PHARMACEUTICAL COMPOSITION AND USE OF COMPOSITE FOR TREATING MENTAL DISORDERS" - Google Patents

"COMPOSITION FOR TREATING MENTAL DISORDERS, BALANCE OF COMPOSITE FOR TREATING MENTAL DISORDERS, PHARMACEUTICAL COMPOSITION AND USE OF COMPOSITE FOR TREATING MENTAL DISORDERS"

Info

Publication number
BRPI0809837A2
BRPI0809837A2 BRPI0809837-9A2A BRPI0809837A BRPI0809837A2 BR PI0809837 A2 BRPI0809837 A2 BR PI0809837A2 BR PI0809837 A BRPI0809837 A BR PI0809837A BR PI0809837 A2 BRPI0809837 A2 BR PI0809837A2
Authority
BR
Brazil
Prior art keywords
mental disorders
treating mental
composite
composition
balance
Prior art date
Application number
BRPI0809837-9A2A
Other languages
Portuguese (pt)
Inventor
Youxin Li
Original Assignee
Youxin Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Youxin Li filed Critical Youxin Li
Publication of BRPI0809837A2 publication Critical patent/BRPI0809837A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0809837-9A2A 2007-04-19 2008-04-18 "COMPOSITION FOR TREATING MENTAL DISORDERS, BALANCE OF COMPOSITE FOR TREATING MENTAL DISORDERS, PHARMACEUTICAL COMPOSITION AND USE OF COMPOSITE FOR TREATING MENTAL DISORDERS" BRPI0809837A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710098304 2007-04-19
PCT/CN2008/000803 WO2008128436A1 (en) 2007-04-19 2008-04-18 Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0809837A2 true BRPI0809837A2 (en) 2014-11-11

Family

ID=39875078

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809837-9A2A BRPI0809837A2 (en) 2007-04-19 2008-04-18 "COMPOSITION FOR TREATING MENTAL DISORDERS, BALANCE OF COMPOSITE FOR TREATING MENTAL DISORDERS, PHARMACEUTICAL COMPOSITION AND USE OF COMPOSITE FOR TREATING MENTAL DISORDERS"

Country Status (9)

Country Link
US (1) US8314110B2 (en)
EP (1) EP2154138B1 (en)
JP (1) JP5315336B2 (en)
KR (1) KR101244185B1 (en)
CN (1) CN101641353B (en)
BR (1) BRPI0809837A2 (en)
DK (1) DK2154138T3 (en)
RU (1) RU2459824C2 (en)
WO (1) WO2008128436A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
CN101889333B (en) 2007-12-17 2012-08-08 日矿金属株式会社 Substrate and method for manufacturing the same
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
PT2529756T (en) 2011-05-31 2021-07-28 Farm Rovi Lab Sa Risperidone and/or paliperidone implant formulation
ES2456917T3 (en) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Paliperidone implant formulation
KR101867988B1 (en) * 2016-11-02 2018-06-15 주식회사 엔지켐생명과학 Paliperidone intermediate and method for producing paliperidone using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
JP3124120B2 (en) * 1992-08-31 2001-01-15 エーザイ株式会社 Method for producing 1-alkyl iodide carbonate
CN1093762A (en) * 1993-04-16 1994-10-19 沈阳石油化工厂 The manufacture method of polyurethane fibre high tenacity fibre rayon
ES2074966B1 (en) * 1994-02-11 1996-06-16 Vita Invest Sa PROCEDURE FOR OBTAINING 3- (2- (4- (6-FLUORO-BENZO (D) ISOXAZOL-3-IL) PIPERIDIN-1-IL) -ETIL) -2-METHYL-6,7,8,9- TETRAHIDRO-4H-PIRIDO- (1,2-A) PIRIMIDIN-4-ONA.
ES2085234B1 (en) * 1994-02-24 1997-01-16 Vita Invest Sa ACTIVE AGENT ON THE CENTRAL NERVOUS SYSTEM, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
CN1160074A (en) * 1996-03-19 1997-09-24 谭兆兴 Method for producing fuel of gas by decomposition of limestone
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (en) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
JP2005060385A (en) * 2003-07-31 2005-03-10 Dainippon Pharmaceut Co Ltd Pharmaceutical comprising 2-furancarboxylic acid hydrazide compound
US7314872B2 (en) * 2003-08-20 2008-01-01 Irm Llc Inhibitors of cathepsin S
WO2005116024A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections
CA2580264A1 (en) * 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same

Also Published As

Publication number Publication date
DK2154138T3 (en) 2015-11-02
RU2459824C2 (en) 2012-08-27
EP2154138A1 (en) 2010-02-17
US8314110B2 (en) 2012-11-20
EP2154138A4 (en) 2011-06-08
KR101244185B1 (en) 2013-03-25
JP5315336B2 (en) 2013-10-16
EP2154138B1 (en) 2015-08-19
CN101641353A (en) 2010-02-03
KR20100016659A (en) 2010-02-12
CN101641353B (en) 2012-05-23
JP2010524863A (en) 2010-07-22
WO2008128436A1 (en) 2008-10-30
US20100113482A1 (en) 2010-05-06
RU2009142595A (en) 2011-05-27

Similar Documents

Publication Publication Date Title
CR8642A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS
CL2007001882A1 (en) COMPOUNDS DERIVED FROM IMIDAZOPIRIMIDINE; PROCESS TO PREPARE THE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE PREVENTION AND / OR TREATMENT OF COGNITIVE DISORDERS.
BRPI0816553A2 (en) "compound, pharmaceutical composition, use of a composition, use of a compound, and process for the preparation of a compound"
BRPI0821115A2 (en) Aminotriazole-derived compound, drug, pharmaceutical composition and use of compound
BRPI0820665A2 (en) peptidyl nitrile compounds, processes for their manufacture, pharmaceutical composition, combination and use of said compounds
BRPI0810956A2 (en) "composition, method for preventive or curative control and use of composition"
CL2007003832A1 (en) COMPOUNDS DERIVED FROM AZAESPIRO; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO PREVENT AND TREAT ANXIETY, DEPRESSIVE DISORDERS, AMONG OTHER DISEASES.
CR10245A (en) "NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION"
BRPI0816881A2 (en) Compound, pharmaceutical composition, use of a compound, and methods for treating diseases or disorders and for preparing a compound.
BRPI0809667A2 (en) COMPOUND, MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
BRPI0818799A2 (en) Compositions for the treatment of parkinson's disease
BRPI0818244A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating a disorder or disease
CL2007002649A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES 2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL] -4-FLUORO- BENZONITRILE; AND USE FOR THE TREATMENT OF DIABETES.
CL2007003672A1 (en) COMPOUNDS DERIVED FROM HETEROARIL-PIRROLIDINIL-CETONA AND HETEROARIL-PIPERIDINIL-CETONA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DEPRESSION AND ANXIETY.
CL2007003635A1 (en) COMPOUNDS DERIVED FROM 6-AMINO-PURIN-8-ONA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCESS TO PREPARE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF ALLERGIC, VIRAL OR CANCER DISEASES.
CL2007001976A1 (en) COMPOUNDS DERIVED FROM DIOXOALCANS AND DIOXOALKENS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT ASTHMA, TOS, PURITO, HYPERSENSITIVITY.
BRPI0813456A2 (en) COMPOSITION, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A MAMMAL WITH A DISORDER AND DISEASE
BRPI0819799A2 (en) Compound, intermediate, use of a compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
BRPI0815324A2 (en) "saccharide-containing protein conjugate, process for separating saccharide-containing protein conjugate, pharmaceutical composition for saccharide-containing protein conjugate, use of saccharide-containing protein conjugate and saccharide-containing protein conjugate compound"
IL216176A (en) (3'-fluoro-4'-(hydroxymethyl)-5'-(methylsulfonyl)biphenyl-4-yl)-2-phenylalkyl-(1h-imidazol-4-yl)propan-2-ol derivatives and pharmaceutical compositions comprising the same
BRPI0922233A2 (en) compounds, pharmaceutical compositions and methods for use in the treatment of metabolic syndromes.
CL2008003592A1 (en) Isoxazolo-pyrazine derived compounds, with selective affinity for the alpha-5 gaba receptor binding site; preparation procedure; pharmaceutical composition; and use in the treatment of cognitive disorders, such as Alzheimer's disease.
BRPI0914371A2 (en) "compound, pharmaceutical composition, use of a compound, method of treating an individual, and combination product"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]